BioPharma Resources

Drug Trial Radar · NCT07662135

A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin

A Randomized, Double-blind, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin (Eluminate-4)

Last checked: Nov 19, 2026Latest source record: Sep 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 900 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

900

Planned (sponsor's estimate)

Start

Jul 6, 2026

Primary completion

Jul 13, 2028

Study completion Jul 13, 2028

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Jun 23, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron, compared with placebo in adults with type 2 diabetes mellitus (T2DM) and impaired renal function, who are or will be on a background of sodium-glucose cotransporter 2 inhibitor (SGLT2i) dapagliflozin 10 mg as per guideline directed medical therapy (GDMT) for chronic kidney disease (CKD). Additionally, participants are on other glucose-lowering medication(s).

Conditions

  • Type 2 Diabetes Mellitus
  • Type 2 Diabetes With Chronic Kidney Disease

Interventions

  • ElecoglipronDrug

    Elecoglipron is administered orally once daily.

  • PlaceboDrug

    Placebo is administered orally once daily.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in Hemoglobin A1c (HbA1c)Time frame: Baseline to Week 40

Locations

186 sites in 16 countries. Site status is shown where the registry gives one.

  • Research Site

    Sun City, Arizona · Not yet recruiting

  • Research Site

    Surprise, Arizona · Not yet recruiting

  • Research Site

    Concord, California · Not yet recruiting

  • Research Site

    Sacramento, California · Recruiting

  • Research Site

    Victorville, California · Not yet recruiting

  • Research Site

    Fleming Island, Florida · Not yet recruiting

  • Research Site

    Lauderdale Lakes, Florida · Not yet recruiting

  • Research Site

    Leesburg, Florida · Not yet recruiting

  • Research Site

    Miami Lakes, Florida · Recruiting

  • Research Site

    Ocoee, Florida · Recruiting

  • Research Site

    Orlando, Florida · Not yet recruiting

  • Research Site

    Chicago, Illinois · Not yet recruiting

  • Research Site

    Braintree, Massachusetts · Not yet recruiting

  • Research Site

    New Bedford, Massachusetts · Not yet recruiting

  • Research Site

    Worcester, Massachusetts · Not yet recruiting

  • Research Site

    Saint Joseph, Michigan · Suspended

  • Research Site

    Saint Paul, Minnesota · Not yet recruiting

  • Research Site

    Kansas City, Missouri · Recruiting

  • Research Site

    Omaha, Nebraska · Not yet recruiting

  • Research Site

    Las Vegas, Nevada · Not yet recruiting

  • Research Site

    Albuquerque, New Mexico · Recruiting

  • Research Site

    The Bronx, New York · Not yet recruiting

  • Research Site

    Kinston, North Carolina · Not yet recruiting

  • Research Site

    Raleigh, North Carolina · Recruiting

  • Research Site

    Winston-Salem, North Carolina · Not yet recruiting

  • Research Site

    Cincinnati, Ohio · Not yet recruiting

  • Research Site

    East Providence, Rhode Island · Not yet recruiting

  • Research Site

    Gaffney, South Carolina · Recruiting

  • Research Site

    Greenville, South Carolina · Not yet recruiting

  • Research Site

    San Antonio, Texas · Suspended

  • Research Site

    San Antonio, Texas · Not yet recruiting

  • Research Site

    Ogden, Utah · Not yet recruiting

  • Research Site

    Arlington, Virginia · Suspended

  • Research Site

    Dupnitsa, Bulgaria · Not yet recruiting

  • Research Site

    Haskovo, Bulgaria · Not yet recruiting

  • Research Site

    Kyustendil, Bulgaria · Not yet recruiting

  • Research Site

    Pleven, Bulgaria · Not yet recruiting

  • Research Site

    Plovdiv, Bulgaria · Not yet recruiting

  • Research Site

    Rousse, Bulgaria · Not yet recruiting

  • Research Site

    Stara Zagora, Bulgaria · Not yet recruiting

Showing 40 of 186 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.